The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 28, 2025
Filed:
Mar. 09, 2018
Applicant:
Cellectis, Paris, FR;
Inventors:
Brian Busser, New York, NY (US);
Philippe Duchateau, Draveil, FR;
Alexandre Juillerat, New York, NY (US);
Laurent Poirot, Paris, FR;
Julien Valton, New York, NY (US);
Assignee:
CELLECTIS, Paris, FR;
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/00 (2006.01); A61K 39/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 5/0783 (2010.01); C12N 5/10 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2803 (2013.01); A61K 39/4611 (2023.05); A61K 39/4631 (2023.05); A61K 39/4636 (2023.05); A61K 39/464413 (2023.05); A61K 39/464419 (2023.05); C07K 16/30 (2013.01); C12N 5/0636 (2013.01); C12N 5/0638 (2013.01); C12N 5/0646 (2013.01); C12N 5/10 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/33 (2013.01);
Abstract
The invention pertains to the field of adaptive cell immunotherapy. It provides with the genetic insertion of exogenous coding sequence(s) that help the immune cells to direct their immune response against infected or malignant cells. These exogenous coding sequences are more particularly inserted under the transcriptional control of endogenous gene promoters that are sensitive to immune cells activation. Such method allows the production of safer immune primary cells of higher therapeutic potential.